The proposed FDA move, contends David Ropiek, director of risk communication at the Harvard Center for Risk Analysis, would needlessly limit an already strained donor supply.

• 对fda已提出的动议，哈佛风险分析中心风险交流部主任大卫 - 罗匹克认为没必要限制已筛选过的供体。